The use of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus induced lymphoma in transplant recipients

B. Savoldo, H. E. Heslop, C. M. Rooney

Research output: Contribution to journalArticle

20 Scopus citations

Abstract

Epstein-Barr Virus Lymphoproliferative Diseases (EBV-LPD) can affect patients receiving allogeneic hemopoietic stem cell or solid organ transplant. They are caused by impairment of EBV specific CD8+ cytotoxic T-lymphocyte (CTL) response due to the immunosuppression that follows these procedures. Despite different therapies LPD can still have a rapid and lethal course. A promising solution is the application of adoptive immunotherapy approaches such as ex vivo generated EBV-specific CTLs for prevention and therapy. Their infusion has been demonstrated to be safe and effective in allogeneic hemopoietic stem cell transplant recipients and their use after allogeneic solid organ transplant is also under evaluation.

Original languageEnglish (US)
Pages (from-to)455-464
Number of pages10
JournalLeukemia and Lymphoma
Volume39
Issue number5-6
DOIs
StatePublished - 2000

Keywords

  • Cytotoxic Tcells
  • EBV-induced lymphoma
  • Prevention
  • Transplantation
  • Treatment

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'The use of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus induced lymphoma in transplant recipients'. Together they form a unique fingerprint.

Cite this